

# G Medical Innovations Holdings Ltd

02:21 02 May 2019

## G Medical Innovations advances mobile health technologies in March quarter

G Medical Innovations Holdings Ltd (ASX:GMV) successfully completed its G Medical Patch pilot program in the UK during the March quarter and is moving to expand the programs as well as commercialise multiple accounts with its affiliates.

During the quarter the company executed a significant purchase order with Hygea Holdings Corp and two of its subsidiaries, Palm Medical Group and AllCare Management Services, Inc for a total of up to about US\$21.85 million.

### G Medical Patch implementation

GMV initiated implementation of the G Medical Patch (extender Holter monitor) within all Hygea's wholly-owned cardiologist physicians.

The phase I launch of the Patch (extender Holter monitor), throughout Hygea's Integrated Physician Association (IPA) network will allow for more than 250 cardiologists, representing more than 400,000 patients, to have access to the new Patch technology.

Further, GMV has started a pilot program with the initial Prizma units with the 'Primary Care Physicians' within Hygea's wholly-owned Independent Group Practices (IPG) for monitoring of their 'chronic condition' patients.

Once the pilot program is fully implemented, the Prizma is anticipated to be adopted across the IPG network, representing an opportunity for more than 2,500 physicians treating about 3.3 million patients.

### READ: G Medical Innovations delivers revenue growth; secures first US commercial order

On April 24, 2019, shareholders approved the conversion of a portion of the company's loan with chief executive officer Yacov Geva to fully paid ordinary shares in the company.

GMV's board of directors' thanks Geva, stating this exemplifies the continued support and faith the CEO has in the future of the company.

The company is also listing its Chinese subsidiary on the HKSE and has been working closely with its legal counsel and lead manager UOB to prepare the A1 submission for the regulator.


G Medical Innovations is also in discussions with several potential underwriters to join UOB in the anticipated IPO.

### READ: G Medical Innovations granted trading halt pending

**Price:** 0.049

**Market Cap:** \$32.57 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** GMV

**Listing:** ASX

**52 week High Low**  
0.21 0.038

**Sector:** Medical technology & services

**Website:** www.gmedinnovations.com

#### Company Synopsis:

*G Medical Innovations Holdings Ltd (ASX:GMV) is listed on the Australian Securities Exchange.*

action@proactiveinvestors.com

## US purchase order update

Throughout the quarter, the company continued to progress dual listing on the NASDAQ with GMV undertaking the final processes surrounding the F1 submission with the US Securities and Exchange Commission.

The company anticipates being able to make the US prospectus public in the coming weeks.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of G Medical Innovations Holdings Ltd named herein, including the promotion by the Company of G Medical Innovations Holdings Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).